---

The First Multi-Cancer Test Panel Using a Single ​Sample of Blood 

Available Initially in California

Proven Technology - Unlimited Possibilities

Aristotle™ has been built on our proprietary mRNA technology platform, which was validated in more than 9,000 patients for the development of the first liquid biopsy for Colorectal Cancer (ColonSentry®).  ColonSentry has been used on 100,000 patients in the U.S. Our scientists are also looking to apply ARISTOTLE to disease states in Gastroenterology, Neurology, Cardiology, and Autoimmune Disorders. Aristotle was selected for online publication at the 2020 annual meeting of the American Society of Clinical Oncology (ASCO). 

Female Panel

• Breast Cancer
• Ovarian Cancer​
• Cervical Cancer
• Endometrial Cancer​
• Liver Cancer
• Colorectal Cancer
• Stomach Cancer​​​​​

Male Panel

• Prostate Cancer​​​
• Liver Cancer
• Colorectal Cancer
• Stomach Cancer​​​​

---

For Employers & Organizations

Sensitivity and Specificity

Aristotle has been demonstrated to identify sets of gene transcripts capable of classifying subjects as having a specific cancer with a high degree of sensitivity and specificity.

Sources:
1) Aristotle: A single blood test for pan-cancer screening.Adam A Dempsey, Samuel Chao, Dimitri Stamatiou, Tanya Pilcz, Jay Ying, and Robert Burakoff; Journal of Clinical Oncology 2020 38:15_suppl, e15037-e15037
​
Aristotle™  was developed and its performance characteristics determined by Stage Zero Life Sciences, Inc.  It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes. The Aristotle™ test must be ordered by and used only in consultation with a healthcare provider who can prescribe medications.